Core Viewpoint - Femasys Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share, now having until July 13, 2026, to meet this requirement [1][2]. Company Compliance Status - The extension does not affect the continued listing status of Femasys' common stock on Nasdaq, and compliance will be confirmed if the stock price remains at or above $1.00 for ten consecutive business days [2]. - Femasys is committed to regaining compliance and plans to monitor its share price closely, taking necessary actions within the extension period [3]. Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [4]. - The company's fertility portfolio includes FemaSeed, which is over twice as effective as traditional IUI, and FemVue, a diagnostic tool for fallopian tube assessment [4]. - FemBloc, a non-surgical permanent birth control method, received regulatory approval in Europe, the UK, and New Zealand in 2025, and is being commercialized through strategic partnerships [5].

Core Points - The Trump administration is taking steps to expand access to in vitro fertilization (IVF), marking a significant move in addressing the high costs associated with the procedure [1][3] - A deal has been struck with EMD Serono to reduce the prices of fertility medications in exchange for tariff relief on imported pharmaceuticals [2] - The administration will encourage employers to offer fertility benefits, although participation is not mandatory, which raises questions about the potential impact on coverage [3][6] Group 1: IVF Accessibility and Cost Reduction - The initiative aims to dramatically reduce the cost of IVF and common fertility drugs, with Trump stating that prices will decrease significantly [3] - IVF can cost around $20,000 or more per cycle, and only 25% of companies with over 200 employees currently provide coverage for the procedure [6] - The U.S. cost of an IVF cycle is 271% higher than the average in 25 other countries, highlighting the need for reform [6] Group 2: Government Actions and Industry Response - EMD Serono, the largest fertility drug manufacturer, will sell IVF therapies directly to patients through a new purchasing site, TrumpRx.gov, set to launch in January 2026 [3][4] - The administration's efforts to lower prescription drug costs include recent agreements with Pfizer and AstraZeneca to improve access to certain medications [4] - An executive order on IVF was issued shortly after Trump took office, but specific details and recommendations have yet to be released [7] Group 3: Public Sentiment and Legal Context - Public support for IVF is strong, with a Pew Research Center poll indicating that 70% of U.S. adults view access to IVF positively [9] - The procedure has become a contentious issue in the broader debate over reproductive rights, particularly following a ruling by Alabama's Supreme Court regarding the status of frozen embryos [8]

New insight tonight into the relationship between Jeffrey Epstein and Galain Maxwell from a trove of purported emails, more than 18,000 published by Bloomberg News, which suggests Maxwell and Epstein were closer in many respects than either publicly admitted. In her July interview with the deputy attorney general, Maxwell, Epstein's convicted co-conspirator, recounts asking Epstein about the initial investigation into him. He said, "I I not to worry. He didn't say he didn't share. I wasn't part of it at all ...

Registration No. 333-281964 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 As filed with the Securities and Exchange Commission on October 16, 2024 Amendment No. 2 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEWGENIVF GROUP LIMITED (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Wing Fung Alfred Siu Chief Executive Officer 1/F, Pier 2, Central (Exact nam ...

As filed with the Securities and Exchange Commission on September 6, 2024 Registration No. 333-____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEWGENIVF GROUP LIMITED (Exact name of registrant as specified in its charter) British Virgin Islands 8090 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Num ...